News   /   Reports

Iran's local vaccine CovPars inches closer to market amid surge in COVID cases

Yusef Jalali
Press TV, Karaj

Among the seven Iranian COVID vaccines, CovPars is making a name for itself. Developed by Razi Serum and Vaccine Research Institute, the recombinant vaccine started the third human trial phase on Sunday.

Iran has so far vaccinated roughly 10 percent of its population. This as the resurgence of the coronavirus in more lethal forms, like the delta variant, has been killing an average of around 500 Iranians every day in the past month.

As the government is scrambling to import more vaccines, CovPars authorities say they are working to get an emergency use license to help speed up the inoculation program.

CovPars is administered in three doses; two intramuscular shots 21 days apart and one intranasal shot one month after the second dose. The third phase is expected to take six months.

As the coronavirus keeps transforming into wilder variants with an unprecedented rate, CovPars developers say they have already launched the production line to accelerate vaccinations. 

The biotech firm says as soon as it gets the emergency use license, it will kick off mass production with the capacity of 3 mn doses per month.

Press TV’s website can also be accessed at the following alternate addresses:

Press TV News Roku